Cover Image
市场调查报告书

球细胞脑白质失养症 (克拉伯病) :开发中产品分析

Globoid Cell Leukodystrophy (Krabbe Disease) - Pipeline Review, H2 2017

出版商 Global Markets Direct 商品编码 408071
出版日期 内容信息 英文 40 Pages
订单完成后即时交付
价格
Back to Top
球细胞脑白质失养症 (克拉伯病) :开发中产品分析 Globoid Cell Leukodystrophy (Krabbe Disease) - Pipeline Review, H2 2017
出版日期: 2017年12月21日 内容信息: 英文 40 Pages
简介

所谓球细胞脑白质失养症 (克拉伯病),是因缺乏被半乳糖神经酰胺酶的酶所引起的退行性疾病。由于缺乏这种酶损害髓磷脂的生长和维持。其症状包括癫痫、肌肉痉挛、失去头部控制、呕吐、发烧、烦躁和大哭。危险因子有家族病史。治疗侧重于管理症状(抗惊厥药,肌肉松弛药)和提供支持性治疗。

k 本报告提供以球细胞脑白质失养症 (克拉伯病) 症的治疗药开发平台现状及最新更新的各开发阶段比较分析,提供您加上最新的新闻和发表之企业和研究机关开发中的治疗药,治疗药评估,后期阶段及中止的计划等相关信息。

简介

  • 调查范围

球细胞脑白质失养症 (克拉伯病) 概要

治疗药的开发

  • 开发中产品;概要
  • 开发中产品;比较分析

企业开发中的治疗药

大学/机关研究中的治疗药

开发中产品概况

  • 临床实验阶段的产品
  • 初期阶段的产品

企业开发中的产品

大学/研究机关研究中的产品

开发治疗药的企业

  • Commence Bio Inc
  • 杏林药业
  • Novartis AG
  • Nuo Therapeutics Inc

治疗药的评估

  • 单剂产品
  • 标的别
  • 各作用机制
  • 各给药途径
  • 各分子类型

药物简介

暂停中的计划

开发中止的产品

产品开发的里程碑

  • 主要消息和新闻稿

附录

图表

本网页内容可能与最新版本有所差异。详细情况请与我们联系。

目录
Product Code: GMDHC9960IDB

Summary:

Global Markets Direct's latest Pharmaceutical and Healthcare disease pipeline guide Globoid Cell Leukodystrophy (Krabbe Disease) - Pipeline Review, H2 2017, provides an overview of the Globoid Cell Leukodystrophy (Krabbe Disease) (Central Nervous System) pipeline landscape.

Krabbe disease also called globoid cell leukodystrophy is a degenerative disorder caused by the deficiency of an enzyme called galactosylceramidase. This enzyme deficiency impairs the growth and maintenance of myelin. Symptoms include seizures, Muscle spasms, Loss of head control, vomiting, fevers, irritability and excessive crying. Risk factors include family history. Treatment focuses on managing symptoms (anticonvulsant, muscle relaxer) and providing supportive care.

Report Highlights:

Global Markets Direct's Pharmaceutical and Healthcare latest pipeline guide Globoid Cell Leukodystrophy (Krabbe Disease) - Pipeline Review, H2 2017, provides comprehensive information on the therapeutics under development for Globoid Cell Leukodystrophy (Krabbe Disease) (Central Nervous System), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The guide covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases.

The Globoid Cell Leukodystrophy (Krabbe Disease) (Central Nervous System) pipeline guide also reviews of key players involved in therapeutic development for Globoid Cell Leukodystrophy (Krabbe Disease) and features dormant and discontinued projects. The guide covers therapeutics under Development by Companies /Universities /Institutes, the molecules developed by Companies in Preclinical and Discovery stages are 2 and 1 respectively. Similarly, the Universities portfolio in Phase I and Preclinical stages comprises 1 and 1 molecules, respectively.

Globoid Cell Leukodystrophy (Krabbe Disease) (Central Nervous System) pipeline guide helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage. The guide is built using data and information sourced from Global Markets Direct's proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

Note: Certain content / sections in the pipeline guide may be removed or altered based on the availability and relevance of data.

Scope:

  • The pipeline guide provides a snapshot of the global therapeutic landscape of Globoid Cell Leukodystrophy (Krabbe Disease) (Central Nervous System).
  • The pipeline guide reviews pipeline therapeutics for Globoid Cell Leukodystrophy (Krabbe Disease) (Central Nervous System) by companies and universities/research institutes based on information derived from company and industry-specific sources.
  • The pipeline guide covers pipeline products based on several stages of development ranging from pre-registration till discovery and undisclosed stages.
  • The pipeline guide features descriptive drug profiles for the pipeline products which comprise, product description, descriptive licensing and collaboration details, R&D brief, MoA & other developmental activities.
  • The pipeline guide reviews key companies involved in Globoid Cell Leukodystrophy (Krabbe Disease) (Central Nervous System) therapeutics and enlists all their major and minor projects.
  • The pipeline guide evaluates Globoid Cell Leukodystrophy (Krabbe Disease) (Central Nervous System) therapeutics based on mechanism of action (MoA), drug target, route of administration (RoA) and molecule type.
  • The pipeline guide encapsulates all the dormant and discontinued pipeline projects.
  • The pipeline guide reviews latest news related to pipeline therapeutics for Globoid Cell Leukodystrophy (Krabbe Disease) (Central Nervous System)

Reasons to buy:

  • Procure strategically important competitor information, analysis, and insights to formulate effective R&D strategies.
  • Recognize emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage.
  • Find and recognize significant and varied types of therapeutics under development for Globoid Cell Leukodystrophy (Krabbe Disease) (Central Nervous System).
  • Classify potential new clients or partners in the target demographic.
  • Develop tactical initiatives by understanding the focus areas of leading companies.
  • Plan mergers and acquisitions meritoriously by identifying key players and it's most promising pipeline therapeutics.
  • Formulate corrective measures for pipeline projects by understanding Globoid Cell Leukodystrophy (Krabbe Disease) (Central Nervous System) pipeline depth and focus of Indication therapeutics.
  • Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.
  • Adjust the therapeutic portfolio by recognizing discontinued projects and understand from the know-how what drove them from pipeline.

Table of Contents

  • Table of Contents
    • List of Tables
    • List of Figures
  • Introduction
    • Global Markets Direct Report Coverage
  • Globoid Cell Leukodystrophy (Krabbe Disease) - Overview
    • Globoid Cell Leukodystrophy (Krabbe Disease) - Therapeutics Development
    • Pipeline Overview
    • Pipeline by Companies
    • Pipeline by Universities/Institutes
    • Products under Development by Companies
    • Products under Development by Universities/Institutes
  • Globoid Cell Leukodystrophy (Krabbe Disease) - Therapeutics Assessment
    • Assessment by Target
    • Assessment by Mechanism of Action
    • Assessment by Route of Administration
    • Assessment by Molecule Type
  • Globoid Cell Leukodystrophy (Krabbe Disease) - Companies Involved in Therapeutics Development
    • Commence Bio Inc
    • Kyorin Pharmaceutical Co Ltd
  • Globoid Cell Leukodystrophy (Krabbe Disease) - Drug Profiles
    • CMB-200 - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • DUOC-01 - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • ibudilast - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • RND-001 - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • Stem Cell Therapy for Globoid Cell Leukodystrophy - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
  • Globoid Cell Leukodystrophy (Krabbe Disease) - Dormant Projects
  • Globoid Cell Leukodystrophy (Krabbe Disease) - Discontinued Products
  • Globoid Cell Leukodystrophy (Krabbe Disease) - Product Development Milestones
    • Featured News & Press Releases
      • Jan 18, 2016: FDA Grants Rare Pediatric Disease Designation to MediciNova's MN-166 (ibudilast) for the Treatment of Krabbe Disease
      • Jun 03, 2015: MediciNova Announces FDA Granted Orphan Drug Designation to MN-166 (ibudilast) for Krabbe Disease
  • Appendix
    • Methodology
    • Coverage
    • Secondary Research
    • Primary Research
    • Expert Panel Validation
    • Contact Us
  • Disclaimer

List of Tables

  • Number of Products under Development for Globoid Cell Leukodystrophy (Krabbe Disease), H2 2017
  • Number of Products under Development by Companies, H2 2017
  • Number of Products under Development by Universities/Institutes, H2 2017
  • Products under Development by Companies, H2 2017
  • Products under Development by Universities/Institutes, H2 2017
  • Number of Products by Stage and Target, H2 2017
  • Number of Products by Stage and Mechanism of Action, H2 2017
  • Number of Products by Stage and Route of Administration, H2 2017
  • Number of Products by Stage and Molecule Type, H2 2017
  • Globoid Cell Leukodystrophy (Krabbe Disease) - Pipeline by Commence Bio Inc, H2 2017
  • Globoid Cell Leukodystrophy (Krabbe Disease) - Pipeline by Kyorin Pharmaceutical Co Ltd, H2 2017
  • Globoid Cell Leukodystrophy (Krabbe Disease) - Dormant Projects, H2 2017
  • Globoid Cell Leukodystrophy (Krabbe Disease) - Discontinued Products, H2 2017

List of Figures

  • Number of Products under Development for Globoid Cell Leukodystrophy (Krabbe Disease), H2 2017
  • Number of Products under Development by Companies, H2 2017
  • Number of Products under Development by Universities/Institutes, H2 2017
  • Number of Products by Targets, H2 2017
  • Number of Products by Stage and Targets, H2 2017
  • Number of Products by Mechanism of Actions, H2 2017
  • Number of Products by Stage and Mechanism of Actions, H2 2017
  • Number of Products by Routes of Administration, H2 2017
  • Number of Products by Stage and Routes of Administration, H2 2017
  • Number of Products by Molecule Types, H2 2017
  • Number of Products by Stage and Molecule Types, H2 2017
Back to Top